GlassScriptPhysician profile
Maria A Stys
NPI 1740493964
$3,390.21
in general payments reported to CMS, 2019-2025
22 companies · $123 in 2025
The $123 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,196 · 2020: $156 · 2021: $248 · 2022: $156 · 2023: $367 · 2024: $144 · 2025: $123.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $634.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $633.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,504.98 | 2019-2020 | |
| Acist Medical Systems, INC. | $546.30 | 2019 | |
| Abiomed | $322.50 | 2021-2024 | Impella |
| Medtronic, INC. | $276.11 | 2021-2025 | Corevalve Evolut R, Micra |
| Medtronic Vascular, INC. | $127.65 | 2019-2020 | |
| Actelion Pharmaceuticals US, INC. | $111.38 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $70.44 | 2022-2023 | Camzyos |
| United Therapeutics Corporation | $48.69 | 2019-2020 | |
| Pfizer INC. | $41.51 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $39.52 | 2022 | |
| Daiichi Sankyo INC. | $38.40 | 2023 | Injectafer |
| Cardiovascular Systems INC. | $34.89 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $34.39 | 2021-2025 | Lifevest |
| Amgen INC. | $33.99 | 2023-2025 | Repatha, Repatha |
| Philips North America LLC | $27.77 | 2025 | Ambulatory Monitoring & Diagnostics Undivided |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $22.70 | 2023 | Rotapro |
| Regeneron Healthcare Solutions, INC. | $20.21 | 2022 | |
| Novartis Pharmaceuticals Corporation | $19.56 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $19.01 | 2025 | |
| Alnylam Pharmaceuticals INC. | $18.56 | 2024 | Amvuttra |
| Lexicon Pharmaceuticals, INC. | $16.21 | 2023 | Inpefa |
| Portola Pharmaceuticals, LLC | $15.44 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maria Stys listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.